Arbutus Presents New Data on AB-729, AB-836 and AB-101 at :

AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients...

Related Keywords

William Collier , Fung Yuen , Arbutus Biopharma Corporation Nasdaq , Division Of Gastroenterology , Deputy Head Of Department , University Of Hong Kong , International Liver Congress , Webcast Scheduled , Biopharma Corporation , European Association , Chief Executive Officer , Data Poster , Man Fung Yuen , Deputy Head , Lap Chee , Hong Kong , Nasdaq Abus , Arbutus Biopharma Corporation , Arbutus , Arbutus Biopharma , Asl 2022 , Hronic Hbv , Gbv , Asl Poster Presentations , Asl Ilc 2022 ,